Chemical Namemacitentan
Dosage FormTablet (oral; 10mg)
Drug ClassReceptor antagonists
CompanyActelion Pharmaceuticals
Approval Year2013


  • For the treatment of pulmonary arterial hypertension (PAH, WHO Group I) to reduce the risks of disease progression and hospitalization.
Last updated on 6/23/2022

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Opsumit (macitentan) Prescribing Information.2021Actelion Pharmaceuticals US, Inc., South San Francisco, CA